Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an antimuscarinic/anticholinergic with peripheral effects similar to those of atropine. It has antispasmodic and antiemetic properties and has been used in irritable bowel syndrome. Oral, subcutaneous, intramuscular or intravenous administration 2 to 4 times a day.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, short half-life, and low oral bioavailability) make it unlikely that it will pass into breast milk in clinically significant amounts.
Intestinal absorption is practically non-existent (Noguchi 1983), so the little that may pass into breast milk will not be absorbed by the infant.
Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.
The literature on this drug is scarce and it is sold in few countries.